Fenoldopam: A new parenteral antihypertensive: Consensus roundtable on the management of perioperative hypertension and hypertensive crises

  • Oparil S
  • Aronson S
  • Deeb G
 et al. 
  • 5

    Readers

    Mendeley users who have this article in their library.
  • 48

    Citations

    Citations of this article.

Abstract

A panel of clinicians from anesthesiology, surgery, nephrology, hypertension, cardiology, and pharmacology was convened to discuss pharmacologic therapeutics in the management of hypertensive crisis and perioperative hypertension. The panel discussed the advantages and limitations of currently available parenteral drugs, and assessed the potential use of fenoldopam mesylate, a drug in clinical development since 1981, and recently approved by the U.S. Food and Drug Administration (FDA). Fenoldopam is a dopamine receptor (DA1selective) agonist that is a systemic and renal vasodilator. It was concluded that fenoldopam offers significant advantages as a parenterally administered agent for the management of blood pressure in both hypertensive emergencies and in the perioperative setting.

Author-supplied keywords

  • Fenoldopam mesylate
  • Hypertension
  • Hypertensive crisis
  • Perioperative hypertension

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Suzanne Oparil

  • Solomon Aronson

  • G. Michael Deeb

  • Murray Epstein

  • Jerrold H. Levy

  • Robert R. Luther

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free